Rodman & Renshaw Reiterates Myrexis Market Outperform, $6 PT

Rodman & Renshaw reiterated its Myrexis

Market Outperform rating and $6 price target in a research report published today. In the report, Rodman & Renshaw states, " Myrexis is trading well below its cash value despite an Hsp90 inhibitor in Phase 1 and two novel pre-clinical assets in the way of a cancer metabolism inhibitor and an oral anti-interferon program, both with differentiated mechanisms of action ripe for pharma partnering." Later in the report, Rodman & Renshaw notes, "We believe the risk/reward profile of Myrexis shares is exceptionally favorable and recommend that investors build a position in the name." Shares of Myrexis were trading at $2.70 at the time of posting, down 4.63% from Thursday's market close.